Nepafenac

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Nepafenac is a topical ophthalmic NSAID prodrug; this evidence pack does not carry a formally documented original indication (data gap), but the underlying trial and literature record shows extensive, longstanding use for inflammation/pain prevention after cataract surgery and for diabetic macular edema risk reduction. TxGNN's top prediction is the broad category eye disease, supported by 41 clinical trials and 20 publications already in this pack — meaning the "new indication" signal largely reconfirms the drug's known ocular use rather than pointing to a genuinely novel disease area.

Quick Overview

Item	Content
Original Indication	Not formally documented in this evidence pack (data gap, see DG002). Trial/literature evidence within this pack indicates established use for cataract surgery-related ocular inflammation, pain, and macular edema prevention.
Predicted New Indication	Eye disease (broad ocular category)
TxGNN Prediction Score	99.85%
Evidence Level	L1
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not present in the structured drug.original_moa field (data gap DG002). However, the clinical evidence collected in this pack is itself informative: nepafenac is a prodrug that, once instilled topically, is converted intraocularly to amfenac, which inhibits COX-1 and COX-2 to reduce prostaglandin synthesis. This is the pharmacological basis for its established role in preventing and treating ocular inflammation and pain after cataract surgery, and in reducing the risk of postoperative macular edema in diabetic patients.

Because "eye disease" is a broad category rather than a specific new condition, this prediction largely overlaps with nepafenac's known clinical use rather than identifying an unmet, previously untested indication. The original_indications field being empty appears to be a data-capture gap rather than an absence of clinical basis — the pack's own trial set (41 studies, several large Phase 3 pivotal trials with n>800–2,000) already documents this activity. Genuinely novel signals in this pack are weaker: candidates such as optic papillitis (rank 2) and vitreous detachment (rank 10) have plausible mechanistic rationale (anti-inflammatory/COX-inhibition effects on retinal or optic nerve inflammation) but only sparse, indirect, or preclinical support (L3–L4), and several lower-ranked predictions (hypotrichosis, seborrheic keratosis, congenital syndromes) have no clinical or mechanistic link at all and are best treated as model noise.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01853072	Phase 3	Completed	881	Nepafenac 0.3% once-daily superior to vehicle for clinical outcomes in diabetic subjects after cataract surgery
NCT01109173	Phase 3	Completed	2120	Large pivotal trial assessing nepafenac 0.3% for prevention/treatment of postoperative ocular inflammation and pain after cataract extraction
NCT01318499	Phase 2	Completed	1342	Nepafenac 0.3% vs 0.1% vs vehicle for prevention/treatment of postoperative inflammation and pain
NCT03499873	Phase 3	Completed	448	Bioequivalence study of generic vs Ilevro (nepafenac 0.3%) for postoperative pain/inflammation
NCT01021761	Phase 4	Completed	126	Head-to-head comparison of nepafenac (Nevanac) vs other NSAID eye drops on PGE2 inhibition post-phacoemulsification
NCT00939276	Phase 3	Terminated	175	Evaluated nepafenac (Nevanac) for macular edema incidence/severity reduction in diabetic retinopathy after cataract surgery
NCT00494494	Phase 4	Completed	82	Nepafenac 0.1% effect on preventing postoperative cystoid macular edema after uncomplicated cataract surgery
NCT02515045	Phase 4	Completed	59	Compared injectable dropless prophylaxis vs standard topical regimen (including nepafenac) after phacoemulsification
NCT03851172	Phase 2	Unknown	75	Nepafenac vs ketorolac for preventing intraoperative miosis during cataract surgery
NCT00801905	Phase 2	Terminated	50	Topical nepafenac for preventing/treating macular thickening related to pan-retinal photocoagulation in diabetic retinopathy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34120417	2021	RCT	Korean J Ophthalmol	Compared 0.1% nepafenac vs 1% prednisolone acetate for postoperative inflammation control after micro-incisional cataract surgery
32672612	2020	RCT	Ophthalmology. Glaucoma	Compared 0.1% nepafenac vs 1% prednisolone acetate for inflammation control after laser peripheral iridotomy
39936354	2025	Systematic Review/Meta-analysis	Eur J Ophthalmol	Nepafenac's role in preventing macular swelling and improving visual outcome after cataract surgery
24345529	2014	Phase 3 Study	J Cataract Refract Surg	Once-daily nepafenac 0.3% to prevent/treat ocular inflammation and pain after cataract surgery
30284393	2018	Cohort/Comparative	Acta Ophthalmol	Clinical efficacy and tolerability of nepafenac vs preservative-free diclofenac after cataract surgery
29199864	2018	Safety/Efficacy Study	Curr Eye Res	Intracameral nepafenac safety and efficacy in inhibiting prostaglandin synthesis during phacoemulsification
26474497	2016	PK/Distribution Study	Exp Eye Res	Distribution of topical nepafenac and its active metabolite amfenac to the posterior segment of the eye
22795976	2012	Comparative Study	J Cataract Refract Surg	Prophylactic nepafenac and ketorolac vs placebo in preventing postoperative macular edema
30046541	2018	Comparative Study	Int J Ophthalmol	Efficacy/safety comparison of bromfenac, nepafenac, and diclofenac for cystoid macular edema prevention
35025078	2022	Review	Drugs	Review of diagnostic agents and therapeutic medications (including NSAIDs) for non-infectious corneal injury

Safety Considerations

Please refer to the package insert for safety information. Formal TFDA/Fimea warnings, contraindications, and drug-drug interaction data were not retrievable at the time of this pack's generation (data gap DG001, classified as Blocking — this prevents a formal S1 safety pre-assessment).

Other TxGNN-Predicted Indications (Screening Notes)

Ranks 2–10 were also screened but are not the focus of this report given weaker or absent evidence:

Rank	Disease	Score	Evidence Level	Recommendation
2	Optic papillitis	99.84%	L4	Hold
3	Hypotrichosis simplex of the scalp	99.84%	L5	Hold
4	Seborrheic keratosis	99.83%	L5	Hold
5	von Hippel anomaly	99.82%	L5	Hold
6	Congenital hypotrichosis milia	99.82%	L5	Hold
7	McPherson Robertson Cammarano syndrome	99.82%	L5	Hold
8	Lagophthalmos	99.81%	L5	Hold
9	Vulvar inverted follicular keratosis	99.81%	L5	Hold
10	Vitreous detachment	99.81%	L3	Research Question

Ranks 3, 4, 6, 7, 8, and 9 have no supporting clinical trials or literature and no plausible mechanistic link to nepafenac's COX-inhibition activity — these likely reflect model noise. Vitreous detachment (rank 10) has one completed Phase 4 trial on vitreous inflammatory biomarkers and warrants a research question rather than immediate dismissal.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The top prediction ("eye disease") is backed by L1-level evidence (multiple completed Phase 3 RCTs), but it substantially overlaps with nepafenac's already-established ophthalmic anti-inflammatory use rather than representing a distinct novel indication — so this should be treated as evidence consolidation, not new-indication discovery. A blocking safety data gap (DG001) also prevents formal risk sign-off.

To proceed, the following is needed:

TFDA/Fimea package insert (warnings, contraindications) to close the blocking safety gap (DG001)
Confirmed original indication and MOA documentation from DrugBank/regulatory sources to properly scope what counts as "new" vs. already-approved use (DG002)
If pursuing rank 10 (vitreous detachment) as a genuine research question, targeted literature/trial search specific to vitreous detachment rather than secondary post-surgical vitreous inflammation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.